Cellceutix Receives FDA Orphan Drug Designation for Kevetrin for the Treatment of Retinoblastoma
November 23, 2015 07:30 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - November 23, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Selects Docetaxel for Combination Arm in Planned Phase 2 Trial for Ovarian Cancer
November 16, 2015 07:30 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - November 16, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Completes Cohort in Kevetrin Clinical Trial; Cheers to Ocata Therapeutics
November 11, 2015 10:34 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - November 11, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Files Form 10-Q for Quarter Ended September 30, 2015
November 10, 2015 10:51 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - November 10, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Provides Brilacidin Update; New Class of Antibiotics to Enter Phase 3
October 30, 2015 07:30 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - October 30, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix to Request Meeting With FDA for Phase 2 Ovarian Cancer Study; Company's First-in-Human Study Defines the Pharmacokinetic Profile of Kevetrin
October 26, 2015 07:40 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - October 26, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Responds to Rosen Law Firm
October 22, 2015 14:28 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - October 22, 2015) - Cellceutix Corporation (OTC: CTIX), Cellceutix was created to tackle some of the worst diseases known to man. We are a company that firmly believes in...
Cellceutix Announces Date for Annual Meeting
October 21, 2015 07:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - October 21, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Chief Scientific Officer Dr. Krishna Menon Speaking at World Anti-Microbial Resistance Congress USA 2015
October 15, 2015 10:04 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - October 15, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Provides Update on Its Phase 3 Preparations for ABSSSI
October 13, 2015 07:30 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - October 13, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...